Once completed, the biotech plant is expected to produce pharmaceutical ingredients from cell cultures.
Georgia/USA – Wood has been awarded a multi-million dollar contract by Teva Biotech to provide engineering, procurement, construction management, commissioning and qualification for a new biotechnological facility to be built in Ulm, Germany.
The plant will produce pharmaceutical ingredients from cell cultures in a new eight-storey building to be constructed within Teva’s existing biotechnology production site. Wood EAAA Capital Projects Group will execute detailed design and procurements services for a lump sum fee, as well as construction management and commissioning/qualification services under a reimbursable contract. Expected completion will be 2020, while tech transfer is planned to begin in 2021.
Prior to this award, Wood completed basic design and an investment cost estimate for the same facility under a previous contract, which was awarded on a competitive basis.